Clinical Trial Detail

NCT ID NCT01525082
Title Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stanford University
Indications

islet cell tumor

Therapies

Bevacizumab + Capecitabine + Temozolomide

Age Groups: adult

No variant requirements are available.